High Expression of IGSF10 Confers an Inhibitory Effect on the Progression of Lung Adenocarcinoma.

Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths worldwide. Unlike conventional treatments, the targeted therapies or emerging immunotherapies have shown significant advantages in the management of advanced lung cancer. Therefore, exploring novel predictive biomarkers or therapeutic targets is still of far-reaching significance for the future treatment of lung cancer. This study revealed that low expression of IGSF10, an important member of the immunoglobulin superfamily, significantly correlates with poor overall survival of lung adenocarcinoma (LUAD) patients and strong tumorigenic capacity of LUAD cells. Mechanistically, high expression of IGSF10 can inhibit the epithelial-mesenchymal transition of LUAD cells via p53-triggering ferroptosis and impede G(1)/S cell cycle transition of LUAD cells via the p53-p21 axis, leading to suppression of LUAD cell migration, growth and tumorigenic capacity. Our findings clarified the specific role of IGSF10 in LUAD, and theoretically suggested new avenues for the presumable IGSF10-targeting therapy of lung cancer in the future.